In ALS, motor neurons degenerate or die, and stop sending messages to the muscles, which gradually weaken and waste away. The other promising treatment NurOwn by Brainstorm Therapeutics Inc is undergoing phase 3 clinical trial in the United States, and will not get FDA approved until 2022. NurOwn(autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.